Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.01). On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kyverna Therapeutics Stock Down 0.9 %

Shares of NASDAQ KYTX opened at $2.11 on Friday. The company has a market cap of $91.19 million, a price-to-earnings ratio of -0.61 and a beta of 2.17. Kyverna Therapeutics has a 12-month low of $1.78 and a 12-month high of $17.55. The firm’s 50-day simple moving average is $2.18 and its 200 day simple moving average is $3.37.

Analysts Set New Price Targets

Several research firms have recently commented on KYTX. Morgan Stanley decreased their price target on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 1st. HC Wainwright lowered their target price on Kyverna Therapeutics from $6.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, April 3rd. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $18.33.

Institutional Investors Weigh In On Kyverna Therapeutics

An institutional investor recently raised its position in Kyverna Therapeutics stock. Bank of America Corp DE raised its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 41.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,788 shares of the company’s stock after buying an additional 6,400 shares during the quarter. Bank of America Corp DE owned about 0.05% of Kyverna Therapeutics worth $81,000 at the end of the most recent reporting period. 18.08% of the stock is owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.